Cardiosense, Inc. — SEC Form D Filing

Cardiosense, Inc. filed an SEC Form D on August 24, 2026, reporting $26.14M raised in Other Health Care.

Form D filing details

Filing
SEC Form D
Filing date
August 24, 2026
Amount reported
$26.14M
Round stage
Series B, inferred from the $26.1 million raised through the conversion of promissory notes to equity to scale clinical validation and commercialization.
Industry
Other Health Care
Website
https://www.cardiosense.com

What the company does

Securities: Equity, Convertible Promissory Notes have converted into equity in connection with this transaction. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Heart failure patients lack continuous, noninvasive, and accurate hemodynamic monitoring at home, leading to preventable hospitalizations and delayed clinical interventions.

Solution

Cardiosense builds AI-powered, noninvasive wearable sensing hardware and software that provides continuous hemodynamic assessment for patients with heart failure.

Why now

Recent advancements in AI-driven physiological algorithms and the growing clinical adoption of remote patient monitoring technologies enable continuous, medical-grade cardiac assessment outside of traditional hospital settings.

Source: SEC EDGAR Form D filing